Search
Search Results
-
Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease
BackgroundAlzheimer disease (AD) is a major health problem of aging, with tremendous burden on healthcare systems, patients, and families globally....
-
Commentaries: Lecanemab: pioneering the way as the first approved drug for Alzheimer’s disease treatment
Alzheimer's disease (AD) is a progressive neurodegenerative disorder marked by cognitive decline and neuronal abnormalities. Current therapies...
-
Lecanemab in patients with early Alzheimer’s disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study
BackgroundLecanemab, a humanized IgG1 monoclonal antibody that targets soluble aggregated Aβ species (protofibrils), has demonstrated robust brain...
-
Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer’s disease
BackgroundLecanemab (BAN2401) is a humanized IgG1 monoclonal antibody that preferentially targets soluble aggregated Aβ species (protofibrils) with...
-
Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer’s Disease
Immunotherapy against amyloid-beta (Aβ) is a promising option for the treatment of Alzheimer’s disease (AD). Aβ exists as various species, including...
-
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
BackgroundLecanemab (BAN2401), an IgG1 monoclonal antibody, preferentially targets soluble aggregated amyloid beta (Aβ), with activity across...
-
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease
Two monoclonal antibodies (mAbs), aducanumab and lecanemab, have received accelerated approval from the US FDA for initiation of treatment in early...
-
The search for clarity regarding “clinically meaningful outcomes” in Alzheimer disease clinical trials: CLARITY-AD and Beyond
CLARITY-AD is an 18-month, double-blinded, placebo-controlled, phase 3 trial which examined the safety and efficacy of the anti-amyloid agent,...
-
“If You Change the Way You Look at Things, Things You Look at Change”
The exact causes of Alzheimer’s disease are still largely elusive and under dispute. The focus on amyloid beta as the central trigger of the disease...
-
Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update
Alzheimer's disease (AD) is the leading cause of dementia, presenting a significant unmet medical need worldwide. The pathogenesis of AD involves...
-
Passive immunotherapy for Alzheimer’s disease: challenges & future directions
Passive immunotherapy with specific antibodies targeting Amyloid β (Aβ) peptide or tubulin-associated unit (tau) protein has emerged as a promising...
-
Anti-Amyloid Immunotherapies for Alzheimer’s Disease: A 2023 Clinical Update
The amyloid cascade hypothesis is a useful framework for therapeutic development in Alzheimer’s disease (AD). Amyloid b 1-42 (Aβ) has been the main...
-
The Amyloid Cascade Hypothesis Has to Deliver, Finally
The Alzheimer’s field has been intensively searching for a therapy, especially in the last 30 years, while the number of affected individuals has...
-
Paradigm Shift: Multiple Potential Pathways to Neurodegenerative Dementia
Neurodegenerative dementia can result from multiple underlying abnormalities, including neurotransmitter imbalances, protein aggregation, and other...
-
Recent advances in Alzheimer’s disease pathogenesis and therapeutics from an immune perspective
BackgroundThe prevalence of Alzheimer’s disease, the most common type of dementia, is continuously increasing. Many recent reports have indicated...
-
Driving Forces of Alzheimer’s Research Directions
Quite a number of influential factors impact the course of biomedical research. Regarding Alzheimer’s disease, some factors appear to have had a...
-
Is the Persistence of the Amyloid Cascade Hypothesis a Result of Constant Confirmation Bias?
Whenever a hypothesis has been around for a very long time, chances are that it has a constantly growing number of followers and a diminishing number...
-
-
Introduction
Alzheimer’s disease is the most frequent type of dementia and an imminent medical problem of our society. Worldwide, millions of individuals are...